(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 September 2008 (12.09.2008)

PCT

(10) International Publication Number
WO 2008/107479 A1

(51) International Patent Classification:
C07D 401/04 (2006.01) *A61P 25/28* (2006.01)
A61K 31/4545 (2006.01)

(21) International Application Number:
PCT/EP2008/052766

(22) International Filing Date: 7 March 2008 (07.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07103654.5 7 March 2007 (07.03.2007) EP
PCT/EP2007/052442
15 March 2007 (15.03.2007) EP
07116401.6 14 September 2007 (14.09.2007) EP

(71) Applicants *(for all designated States except US)*: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). **ADDEX PHARMA S.A.** [CH/CH]; 12, Chemin des Aulx, CH-1228 Plan-les-Ouates (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CID-NÚÑEZ, José, Maria** [ES/ES]; c/o Johnson & Johnson, Pharmaceutical Research and Development, Division of Janssen-Cilag, S.A, Calle Jarama, 75, Poligono Industrial (ES). **TRABANCO-SUÁREZ, Andrés, Avelino** [ES/ES]; c/o Johnson & Johnson, Pharmaceutical Research and Development, Division of Janssen-Cilag, S.A, Calle Jarama, 75, Poligono Industrial (ES). **MACDONALD, Gregor, James** [GB/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **DUVEY, Guillaume, Albert, Jacques** [FR/FR]; c/o ADDEX Pharma S.A., 12, Chemin des Aulx, CH-1228 Plan-les-Ouates (CH). **LÜTJENS, Robert, Johannes** [DE/CH]; c/o ADDEX Pharma S.A., 12, Chemin des Aulx, CH-1228 Plan-les-Ouates (CH).

(74) Common Representative: **JANSSEN PHARMACEUTICA NV**; Turnhoutseweg 30, B-2340 Beerse (BE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*

(54) Title: 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES



(I")

(57) Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic glutamate receptors subtype 2 (" mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are centralnervous system disorders selected from the group of anxiety,schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and such compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

WO 2008/107479 A1